Quantcast
Last updated on April 17, 2014 at 1:21 EDT

Latest Non-steroidal anti-inflammatory drug Stories

2008-10-20 09:00:42

Pfizer has reached agreements in principle to resolve substantially all of the personal injury cases, consumer fraud cases and state attorneys general claims involving its non-steroidal anti-inflammatory pain medication Bextra, which the company voluntarily withdrew from the US market in 2005. Additionally, following key court rulings in favor of Celebrex, claims regarding Celebrex, a pain treatment, will also be resolved as part of the settlement. The announcement follows favorable...

2008-09-03 09:00:08

HOBOKEN, N.J., Sept. 3 /PRNewswire/ -- According to the Center for Disease Control (CDC), osteoarthritis, the most common type of arthritis, is on the rise. A new study published in the August journal of Phytotherapy Research, reveals Pycnogenol(R), bark extract from the French maritime pine tree, reduced overall knee osteoarthritis (OA) symptoms by 20.9 percent and lowered pain by 40.3 percent. To date, this is the third clinical trial on osteoarthritis treatment with Pycnogenol(R). This...

2008-08-25 09:01:58

MONTVALE, N.J., Aug. 25, 2008 (GLOBE NEWSWIRE) -- Ivivi Technologies, Inc. (Nasdaq:IVVI), a leader in non-invasive, electroceutical therapy systems designed to target and enhance the body's anti-inflammatory and angiogenic responses, today announced that patient enrollment has been initiated at the Henry Ford Hospital, Detroit, Michigan, for a randomized, double-blinded, placebo-controlled study on the efficacy of Ivivi's targeted proprietary pulsed electromagnetic field (tPEMF(tm))...

2008-08-09 03:00:08

By Brune, Kay Katus, Hugo A; Moecks, Joachim; Spanuth, Eberhard; Jaffe, Allan S; Giannitsis, Evangelos BACKGROUND: We investigated whether higher concentrations of N- terminal pro-B-type natriuretic peptide (NT-proBNP) predicts cardiovascular adverse events (CV-AEs) in patients with osteoarthritis treated with antiinflammatory drugs. METHODS: NT- proBNP was measured in baseline samples from 433 patients enrolled in a prospective randomized study designed to test the therapeutic effect of a...

2008-06-27 12:01:44

BOSTON, June 27 /PRNewswire-FirstCall/ -- Patients suffering from probable migraine, which is defined as a sub-type of migraine that meets all but one of the migraine diagnostic criteria, frequently have difficulty finding effective treatment. To date, no available migraine-specific medications have proven effective in treating this migraine sub-type. However, according to new data, Treximet is the first migraine-specific medication to demonstrate pain-free results in patients with probable...

2008-06-27 12:01:39

BOSTON, June 27 /PRNewswire-FirstCall/ -- New data offer hope for migraine sufferers who report that they have poor response or are intolerant to their migraine therapy. Two studies of migraineurs who reported that they had poor response to, or did not tolerate, short-acting triptans, showed that treatment with Treximet provided sustained pain-free results at two through 24 hours and was generally well-tolerated. These studies were presented today at the 50th Annual Scientific Meeting of...

2008-06-25 06:03:22

Morria Biopharmaceuticals has initiated a Phase II equivalent study of MRX-4, in a nasal aerosol formulation, in 105 patients suffering from allergic rhinitis. The two-arm, randomized, multi-dose, double-blind, placebo-controlled study includes Rhinocort as the steroid comparator arm. The study is expected to be completed by the end of third quarter 2008. The study is designed to evaluate the safety, tolerability, and efficacy of intranasal MRX-4 in allergic rhinitis (AR) patients outside...

2008-06-24 12:02:09

TAMPA, Fla., June 24 /PRNewswire/ -- Sirion Therapeutics, Inc., a privately held ophthalmic-focused biopharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has approved its new drug application for Durezol(TM) (difluprednate ophthalmic emulsion) 0.05%, a topical steroid for the treatment of postoperative ocular inflammation and pain. The approval came after a six month priority review. (Logo: http://www.newscom.com/cgi-bin/prnh/20080220/CLW064LOGO )...

2008-06-18 09:01:17

HOBOKEN, N.J., June 18 /PRNewswire/ -- A new study reveals dysmenorrhea, a condition that causes extremely painful menstrual periods affecting millions of women each year, can be reduced naturally by taking Pycnogenol(R) (pic-noj- en-all), pine bark extract from the French maritime pine tree. The multi- center field study, published in the Journal of Reproductive Medicine, shows women with dysmenorrhea who supplemented with Pycnogenol(R) experienced less pain and required less pain...

91f57cd19b6d4c0d30b17426f4cade9b1
2008-03-25 12:45:00

Researchers looking for an alternative to non-steroidal anti-inflammatory drugs (NSAIDs), found that 10g of cod liver oil each day could be beneficial for people who suffer from rheumatoid arthritis.The Dundee University team published their study in the journal "ËœRheumatalogy.' Their findings showed that by taking a cod liver oil supplement, people could reduce their reliance on anti-inflammatory drugs by more than 30 percent.Professor Jill Belch at the University of Dundee School...